<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04653480</url>
  </required_header>
  <id_info>
    <org_study_id>APHRODITE</org_study_id>
    <nct_id>NCT04653480</nct_id>
  </id_info>
  <brief_title>Surufatinib, Toripalimab and Chemotherapy in Second-line MT and MSS CRC</brief_title>
  <official_title>Surufatinib and Toripalimab Combined With Chemotherapy for Second-line Treatment of Advanced RAS/BRAF Mutant and Microsatellite Stable Colorectal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zhejiang University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Zhejiang University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To determine the efficacy and safety of surufatinib, toripalimab and chemotherapy in&#xD;
      second-line RAS/BRAF mutant and MSS colorectal cancer&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 1, 2021</start_date>
  <completion_date type="Anticipated">January 2025</completion_date>
  <primary_completion_date type="Anticipated">January 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Response Rate</measure>
    <time_frame>2 months</time_frame>
    <description>the proportion of patients in a trial whose tumor is destroyed or significantly reduced by a drug. ORR is generally defined as the sum of complete responses (CRs) - patients with no detectable evidence of a tumor over a specified time period - and partial responses (PRs) - patients with a decrease in tumor size over a specified time period.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>2 years</time_frame>
    <description>Refers to the time of death from enrollment to any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival</measure>
    <time_frame>6 months</time_frame>
    <description>the time elapsed between treatment initiation and tumor progression</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">61</enrollment>
  <condition>Colorectal Cancer</condition>
  <arm_group>
    <arm_group_label>Surufatinib, Toripalimab and Chemotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Second line CRC patients received surufatinib 250mg po qd , toripalimab 3mg/kg ivgtt q2w and chemotherapy according to the first line treatment, until disease progression or intolerable toxicity</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Surufatinib</intervention_name>
    <description>250mg per oral, once daily</description>
    <arm_group_label>Surufatinib, Toripalimab and Chemotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Toripalimab</intervention_name>
    <description>3mg/kg IV, once every 2 weeks</description>
    <arm_group_label>Surufatinib, Toripalimab and Chemotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>chemotherapy</intervention_name>
    <description>oxaliplatin or irinotecan based regimens, according to the first line treatment</description>
    <arm_group_label>Surufatinib, Toripalimab and Chemotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age ≥ 18 years, ≤75 years&#xD;
&#xD;
          2. Histologically confirmed colorectal cancer with distant metastasis.&#xD;
&#xD;
          3. ECOG 0-1&#xD;
&#xD;
          4. Progression on first line therapy&#xD;
&#xD;
          5. RAS/BRAF mutant and microsatellite stable&#xD;
&#xD;
          6. Patients can swallow pills normally&#xD;
&#xD;
          7. Expected overall survival ≥6 months&#xD;
&#xD;
          8. Blood routine: no blood transfusion or blood products usage within 14 days, G-CSF or&#xD;
             other hematopoietic stimulator was not used. WBC counts &gt; 3000/µl，Absolute neutrophil&#xD;
             count (ANC) ≥ 1500 cells/µl，Platelet count ≥ 100,000/µl，Hemoglobin ≥ 9.0 g/dL.&#xD;
&#xD;
          9. AST, ALT and alkaline phosphatase ≤ 2.5 times the upper limit of normal (ULN)，Serum&#xD;
             bilirubin ≤ 1.5 x ULN，creatinine&lt;ULN&#xD;
&#xD;
         10. Prothrombin time (PT), international standard ratio (INR) ≤1.5 × ULN&#xD;
&#xD;
         11. Patients who have not received immunotherapy&#xD;
&#xD;
         12. Women of childbearing age must be willing to use adequate contraceptives during the&#xD;
             study period of drug treatment;&#xD;
&#xD;
         13. Informed consent has been signed.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients have received ≥2 line systemic therapy;&#xD;
&#xD;
          2. Active bleeding within 3 months; Occurrence of arterial/venous thrombosis within 6&#xD;
             months; Hereditary or acquired bleeding (e.g., clotting dysfunction) or thrombotic&#xD;
             tendencies; Full dose oral or injectable anticoagulants or thrombolytic drugs for&#xD;
             therapeutic purposes are currently being used or have been used recently (10 days&#xD;
             prior to the commencement of study treatment); Surgery (except for biopsy) was&#xD;
             performed within 4 weeks prior to the study or the surgical incision was not fully&#xD;
             healed; Aspirin (&gt; 325 mg/ day) or dipyridamole, ticlopidine, clopidogrel, and&#xD;
             silotazole are currently being used or have recently been used (10 days prior to the&#xD;
             study).&#xD;
&#xD;
          3. Systemic corticosteroids or other systemic immunosuppressive drugs were used within 2&#xD;
             weeks prior to treatment. Immunosuppressive drugs were started or expected to be used&#xD;
             during the trial. Inhaled corticosteroids, physiologic replacement doses of&#xD;
             glucocorticoids are allowed.&#xD;
&#xD;
          4. Certain or suspected brain metastases.&#xD;
&#xD;
          5. The patient has a history of autoimmune disease.&#xD;
&#xD;
          6. Serious uncontrolled systemic diseases, such as severe active infections;&#xD;
&#xD;
          7. A person is known to be infected with the immunodeficiency virus (HIV) or known to be&#xD;
             HIV-positive;&#xD;
&#xD;
          8. Patients have suffered from other malignancies in the past 5 years except cervical&#xD;
             carcinoma in situ or basal cell carcinoma of the skin&#xD;
&#xD;
          9. Untreated chronic hepatitis B or chronic hepatitis B virus (HBV) carriers (HBV DNA&#xD;
             &gt;500 IU/mL) or active HCV carriers with HCV RNA can be detected. Remarks: Inactive&#xD;
             hepatitis B surface antigen (HBsAg) carriers, treated and stable hepatitis B patients&#xD;
             (HBV DNA &lt; 500 IU/mL) may be enrolled&#xD;
&#xD;
         10. Anti-infective therapy was not discontinued 14 days before the study;&#xD;
&#xD;
         11. A prior history of interstitial lung disease, drug-induced interstitial lung disease,&#xD;
             radiation pneumonia, and symptomatic interstitial lung disease or the presence of&#xD;
             active pneumonia on a chest CT scan within 4 weeks prior to the study.&#xD;
&#xD;
         12. Patients have a history of intestinal obstruction within six months. Patients with&#xD;
             incomplete obstruction syndrome of ileus at the time of initial diagnosis may be&#xD;
             enrolled in the study if they have received definitive (surgical) treatment to resolve&#xD;
             the symptoms, as assessed by the investigator.&#xD;
&#xD;
         13. Patients Have high blood pressure that cannot be well controlled by antihypertensive&#xD;
             medication (systolic ≥140 mmHg or diastolic ≥90 mmHg)&#xD;
&#xD;
         14. Urine routine indicated urinary protein ≥++ and confirmed 24-hour urinary protein&#xD;
             &gt;1.0g;&#xD;
&#xD;
         15. Known to be allergic to any study drug;&#xD;
&#xD;
         16. Patients have participated in other drug clinical studies within 4 weeks before&#xD;
             enrollment;&#xD;
&#xD;
         17. Lactating women&#xD;
&#xD;
         18. According to the judgment of the researcher, the patient may have other factors that&#xD;
             may affect the results of the study or cause the study to be terminated, such as&#xD;
             alcohol abuse, drug abuse, other serious diseases (including mental diseases)&#xD;
             requiring combined treatment. Patients have severe laboratory abnormalities, which&#xD;
             will affect the safety of the patient.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Weijia Fang, MD.</last_name>
    <phone>+86-571-87235147</phone>
    <email>weijiafang@zju.edu.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>First affiliated hospital, Zhejiang University</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310006</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Weijia fang, MD</last_name>
    </contact>
    <investigator>
      <last_name>Weijia fang, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>November 28, 2020</study_first_submitted>
  <study_first_submitted_qc>November 28, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 4, 2020</study_first_posted>
  <last_update_submitted>February 8, 2021</last_update_submitted>
  <last_update_submitted_qc>February 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Zhejiang University</investigator_affiliation>
    <investigator_full_name>Weijia Fang, MD</investigator_full_name>
    <investigator_title>Director of Medical Oncology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

